4-((9H-carbazol-9-yl)methyl)benzoic acid | 1257983-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-((9H-carbazol-9-yl)methyl)benzoic acid
• 英文别名: 4-(Carbazol-9-ylmethyl)benzoic acid
• CAS: 1257983-72-4
• 化学式: C₂₀H₁₅NO₂
• 分子量: 301.345
• InChiKey: SWMSEGFTVOXUCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-((9H-carbazol-9-yl)methyl)benzoic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-(Carbazol-9-ylmethyl)benzoyl chloride
  参考文献：
  名称：

  Discovery of novel PTP1B inhibitors via pharmacophore-oriented scaffold hopping from Ertiprotafib

  摘要：

  An integrated molecular design strategy combining pharmacophore recognition and scaffold hopping was exploited to discover novel PTP1B inhibitors based on the known PTP1B inhibitor Ertiprotafib. A composite pharmacophore model was proposed from the interaction mode of Ertiprotafib, and 21 diverse molecules from five distinct structural classes were designed and synthesized accordingly. New compounds with considerable inhibition against PTP1B were identified from each series, and the most active compound 3a showed IC50 value of 1.3 mu mol L-1 against human recombinant PTP1B. Docking study indicated that the new inhibitors assumed binding modes similar to that of Ertiprotafib. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.002
• 作为产物：
  描述：

  对甲基苯甲酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydroxide 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 水 为溶剂， 反应 90.0h， 生成 4-((9H-carbazol-9-yl)methyl)benzoic acid
  参考文献：
  名称：

  苯甲酰胺基羧酸类化合物及其制法和药物用途

  摘要：

  本发明公开了式I化合物所示新的苯甲酰胺基羧酸类化合物，其旋光异构体及外消旋体，和其生理上可接受的盐，溶剂化物以及结晶形式，所述化合物的制备方法，含有所述化合物的药物制剂，以及所述化合物在治疗与胰岛素抗性有关的临床中的应用。

  公开号：

  CN102030700B

文献信息

• HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME
  申请人：Kozikowski Alan

  公开号：US20120252740A1

  公开（公告）日：2012-10-04

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

  本文披露了组蛋白去乙酰化酶抑制剂（HDACIs）及其含量。同时还披露了治疗疾病和状况的方法，其中抑制HDAC能够提供益处，如癌症、神经退行性疾病、神经系统疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。
• HDAC Inhibitors and Therapeutic Methods of Using Same
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US20130281484A1

  公开（公告）日：2013-10-24

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

  本文披露了组蛋白去乙酰化酶抑制剂（HDACIs）及其组合物。同时还披露了治疗疾病和状况的方法，其中抑制HDAC可以提供益处，例如癌症、神经退行性疾病、神经系统疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。
• Synthesis and Characterization of Six New Carbazolyl Porphyrins
  作者：Dong-Cai Guo、Ping-Liang Li、Xin Wang、Li-Ying Wang、Pan-Liang Wu

  DOI：10.1080/00397910903419811

  日期：2010.10.20

  Novel 4-(N-carbazole methyl) benzoic acid and N-carbazolacetic acid are synthesized, then six new carbazolyl porphyrins are synthesized by bonding these acids to hydroxy porphyrin or amido porphyrin via acyl chloride or N,N'-dicyclohexylcarbodiimide (DCC)-dimethylaminopyndine methods. The formations of these title compounds, as well as their intermediates are characterized by 1H NMR, mass spectrometry, Fourier transform-infrared, and elemental analysis.
• First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
  作者：Kairui Yue、Simin Sun、Geng Jia、Mengting Qin、Xiaohan Hou、C. James Chou、Chao Huang、Xiaoyang Li

  DOI：10.1021/acs.jmedchem.2c00853

  日期：2022.9.22
• HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：The Board of Trustees of the University of Illinois

  公开号：EP2456757B1

  公开（公告）日：2019-05-01